Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia.
Adolescent
Canada
/ epidemiology
Child
Child, Preschool
Female
Follow-Up Studies
Graft vs Host Disease
/ diagnosis
Health Services Accessibility
/ statistics & numerical data
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Incidence
Infant
Leukemia, Myeloid, Acute
/ pathology
Male
Neoplasm Recurrence, Local
/ diagnosis
Prognosis
Retrospective Studies
Transplantation Conditioning
Transplantation, Homologous
access to care
acute myeloid leukemia
geographical
hematopoietic stem cell transplant
sociodemographic
universal health care
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
12
2019
revised:
31
01
2020
accepted:
27
02
2020
pubmed:
24
4
2020
medline:
25
8
2020
entrez:
24
4
2020
Statut:
ppublish
Résumé
Indications for hematopoietic stem cell transplantation (HSCT) in pediatric acute myeloid leukemia (AML) are primarily dependent on risk stratification at diagnosis and relapse status. We sought to determine whether access to HSCT is influenced by regional and socioeconomic factors. Children with newly diagnosed AML aged < 15 years between 2001 and 2015 were identified using the Cancer in Young People in Canada national population-based registry. Factors potentially associated with the receipt of HSCT were studied using univariate and multivariable logistic regression models. Overall, 568 children with newly diagnosed AML were included and 262 (46%) received HSCT. A greater proportion of patients, 103/157 (65.6%), underwent HSCT after first or subsequent relapse compared to 159/411 (38.7%) patients who underwent transplant before relapse. Among patients for whom HSCT would be considered before relapse, factors associated with higher odds of HSCT in a multivariable analysis were: poor versus good-risk cytogenetics (Odds ratio [OR]: 30.0, 95% confidence interval [CI]: 7.7-117.0), diagnosis during 2012-2015 versus 2001-2006 (OR: 3.2, 95% CI: 1.6-6.3), diagnosis in eastern Canada versus central Canada (OR: 3.7, 95% CI: 1.9-7.3), and age 10-14 years versus age < 1 year (OR: 5.4, 95% CI: 2.3-12.8). Among patients for whom HSCT would be considered after first relapse, higher odds of HSCT was associated with diagnosis at a HSCT center (OR: 2.1, 95% CI: 1.1-4.1). Patients diagnosed at a HSCT performing center and patients from eastern Canada had higher odds of receiving HSCT. This may suggest preferential access to HSCT for certain patients.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28263Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. J Am Med Assoc. 2010;303(16):1617-1624.
Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol. 1997;15(7):2644-2651.
Milone G, Sacchi N, Gallina A, et al. Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of. Bone Marrow Transplant. 2018;53:291-299.
Morris TCM, Velangi M, Jackson G, Marks DI, Ranaghan L. Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. Br J Haematol. 2005;128(4):510-512.
Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032.
Gibson BES, Webb DKH, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366-376.
Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission. Leukemia. 2014;28(10):1949-1952.
Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015(11):1863-1869. https://doi.org/10.1016/j.bbmt.2015.07.032.
Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases. Bone Marrow Transplant. 2015;50:1037-1056.
Hwang JP, Lam TP, Cohen DS, Donato ML, Geraci JM. Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas. Cancer. 2004;101(10):2230-2238.
Mehta P, Pollock BH, Nugent M, Horowitz M, Wingard JR. Access to stem cell transplantation: do women fare as well as men. Am J Hematol. 2003;72(2):99-102.
Joshua T V, Rizzo JD, Zhang M-JJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116(14):3469-3476.
Schriber JR, Hari PN, Ahn KW, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123(16):3141-3149.
Farnia S, Ganetsky A, Silver A, et al. Challenges around access to and cost of life-saving medications after allogeneic hematopoietic cell transplantation for Medicare patients. Biol Blood Marrow Transplant. 2017;23(8):1387-1392.
Jabo B, Morgan JW, Martinez ME, Ghamsary M, Wieduwilt MJ. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One. 2017;12(4):e0174760.
Paulson K, Lambert P, Bredeson C, et al. Does location matter rural vs urban outcomes after blood and marrow transplantation in a population-based Canadian cohort. Bone Marrow Transplant. 2010;45(7):1167-1173.
Truong TH, Pole JD, Bittencourt H, et al. Access to hematopoietic stem cell transplantation among pediatric patients with acute lymphoblastic leukemia: a population-based analysis. Biol Blood Marrow Transplant. 2019;25(6):1172-1178.
Greenberg ML, Barr RD, DiMonte B, McLaughlin E, Greenberg C. Childhood cancer registries in Ontario, Canada: lessons learned from a comparison of two registries. Int J Cancer. 2003;105(1):88-91.
Cancer in Young People in Canada: a report from the enhanced childhood cancer surveillance system. Health Promot Chronic Dis Prev Can.2017;37(11):393. https://www.canada.ca/en/health-canada/services/publications/science-research-data/cancer-young-people-canada-surveillance-2017.html#appb. Accessed January 21, 2020.
Children's Oncology Group cooperative trial AAML0531 and AAML1031 (Protocol for treatment of Acute Myeloid Leukemia) https://www.childrensoncologygroup.org.
Borugian MJ, Spinelli JJ, Mezei G, Wilkins R, Abanto Z, McBride ML. Childhood leukemia and socioeconomic status in Canada. Epidemiology. 2005;16(4):526-531.
Darmawikarta D, Pole JD, Gupta S, Nathan PC, Greenberg M. The association between socioeconomic status and survival among children with Hodgkin and non-Hodgkin lymphomas in a universal health care system. Pediatr Blood Cancer. 2013;60(7):1171-1177.
Gupta S, Sutradhar R, Guttmann A, Sung L, Pole JD. Socioeconomic status and event free survival in pediatric acute lymphoblastic leukemia: a population-based cohort study. Leuk Res. 2014;38(12):1407-1412.
Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the United States: a Center for International Blood and Marrow Transplant Research report. Biol Blood Marrow Transplant. 2017. https://doi.org/10.1016/j.bbmt.2017.04.018.
Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138.
Tarlock K, Alonzo TA, Moraleda PP, et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br J Haematol. 2014;166:254.
Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661.
Staffas A, Kanduri M, Hovland R, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905-5913.
Loberiza FR, Cannon AJ, Weisenburger DD, et al. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol. 2009;27(32):5376-5382.
Paulson K, Brazauskas R, Khera N, etal. Inferior access to allogeneic transplant in disadvantaged populations: a CIBMTR analysis. Biol Blood Marrow Transplant. 2019; 25(10):2086-2090.